Management of immune thrombocytopenia in elderly patients

Rodeghiero, 2009, vol. 113, 2386 Cines, 2002, Immune Thrombocytopenic Purpura, N Engl J Med, 346, 995, 10.1056/NEJMra010501 Stasi, 2012, How to approach thrombocytopenia, Hematology Am Soc Hematol Educ Program, 2012, 191, 10.1182/asheducation.V2012.1.191.3798260 Harrington, 1990, Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura, J Lab Clin Med, 115, 636 Nugent, 2009, Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production, Br J Haematol, 146, 585, 10.1111/j.1365-2141.2009.07717.x Semple, 1996, Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity, Blood, 87, 4245, 10.1182/blood.V87.10.4245.bloodjournal87104245 Panitsas, 2004, Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response, Blood, 103, 2645, 10.1182/blood-2003-07-2268 Zhao, 2008, Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies, Haematologica, 93, 1428, 10.3324/haematol.12889. Olsson, 2003, T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura, Nat Med, 9, 1123, 10.1038/nm921 Liu, 2007, Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura, Eur J Haematol, 78, 139 Yu, 2008, Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura, Blood, 112, 1325, 10.1182/blood-2008-01-135335 Li, 2012, Defective regulatory B-cell compartment in patients with immune thrombocytopenia, Blood, 120, 3318, 10.1182/blood-2012-05-432575 Olsson, 2008, Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1, Blood, 112, 1078, 10.1182/blood-2008-02-139402 McMillan, 2005, The effect of antiplatelet autoantibodies on megakaryocytopoiesis, Int J Hematol, 81, 94, 10.1532/IJH97.04168 Kosugi, 1996, Circulating thrombopoietin level in chronic immune thrombocytopenic purpura, Br J Haematol, 93, 704, 10.1046/j.1365-2141.1996.d01-1702.x Cooper, 2006, The pathogenesis of immune thrombocytopaenic purpura, Br J Haematol, 133, 364, 10.1111/j.1365-2141.2006.06024.x Audia, 2017, Pathogenesis of immune thrombocytopenia, Autoimmun Rev, 16, 620, 10.1016/j.autrev.2017.04.012 Cines, 2009, Pathobiology of secondary immune thrombocytopenia, Semin Hematol, 46, 10.1053/j.seminhematol.2008.12.005 Frederiksen, 1999, The incidence of idiopathic thrombocytopenic purpura in adults increases with age, Blood, 94, 909, 10.1182/blood.V94.3.909.415k02_909_913 Neylon, 2003, Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients, Br J Haematol, 122, 966, 10.1046/j.1365-2141.2003.04547.x Marieke Schoonen, 2009, Epidemiology of immune thrombocytopenic purpura in the general practice research database, Br J Haematol, 145, 235, 10.1111/j.1365-2141.2009.07615.x Moulis, 2014, Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France, Blood, 124, 3308, 10.1182/blood-2014-05-578336 Stasi, 1995, Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura, Am J Med, 98, 436, 10.1016/S0002-9343(99)80342-8 Provan, 2010, International consensus report on the investigation and management of primary immune thrombocytopenia, Blood, 115, 168, 10.1182/blood-2009-06-225565 Cooper, 2017, State of the art – how I manage immune thrombocytopenia, Br J Haematol, 177, 39, 10.1111/bjh.14515 Stasi, 2009, Therapeutic strategies for hepatitis- and other infection-related immune thrombocytopenias, Semin Hematol, 46, 10.1053/j.seminhematol.2008.12.006 Hayashi, 2014, Management of thrombocytopenia due to liver cirrhosis: a review, World J Gastroenterol, 20, 2595, 10.3748/wjg.v20.i10.2595 Neunert, 2011, The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia, Blood, 117, 4190, 10.1182/blood-2010-08-302984 McMillan, 2009, Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production, Hematol Oncol Clin North Am, 23, 1163, 10.1016/j.hoc.2009.08.008 Tefferi, 2009, Myelodysplastic syndromes, N Engl J Med, 361, 1872, 10.1056/NEJMra0902908 Rollison, 2008, Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs, Blood, 112, 45, 10.1182/blood-2008-01-134858 Kantarjian, 2007, The incidence and impact of thrombocytopenia in myelodysplastic syndromes, Cancer, 109, 1705, 10.1002/cncr.22602 Waisbren, 2016, Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia, Int J Hematol, 1 Sashida, 2003, Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis, Leuk Lymphoma, 44, 653, 10.1080/1042819031000063507 Bennett, 2009, Drug-induced thrombocytopenia, 487 Reese, 2010, Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods, Blood, 116, 2127, 10.1182/blood-2010-03-276691 Arnold, 2012, Platelet count or bleeding as the outcome in ITP trials, Am J Hematol, 87, 945, 10.1002/ajh.23299 Cortelazzo, 1991, High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura, Blood, 77, 31, 10.1182/blood.V77.1.31.31 Cohen, 2000, The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts, Arch Intern Med, 160, 1630, 10.1001/archinte.160.11.1630 Zhou, 2013, Immune thrombocytopenia in the elderly: Clinical course in 525 patients from a single center in China, Ann Hematol, 92, 79, 10.1007/s00277-012-1567-2 Sarpatwari, 2010, Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom general practice research database, Haematologica, 95, 1167, 10.3324/haematol.2009.018390 Severinsen, 2011, Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study, Br J Haematol, 152, 360, 10.1111/j.1365-2141.2010.08418.x Enger, 2010, Comorbidities in patients with persistent or chronic immune thrombocytopenia, Int J Hematol, 92, 289, 10.1007/s12185-010-0636-3 Ruggeri, 2014, Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors, J Thromb Haemost, 12, 1266, 10.1111/jth.12636 Nørgaard, 2012, Thrombosis in patients with primary chronic immune thrombocytopenia, Thromb Res, 130, 10.1016/j.thromres.2012.08.282 Naess, 2007, Incidence and mortality of venous thrombosis: a population-based study, J Thromb Haemost, 5, 692, 10.1111/j.1538-7836.2007.02450.x Catalá-López, 2012, Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials, Med Clin (Barc), 139, 421, 10.1016/j.medcli.2011.11.023 Rodeghiero, 2016, Is ITP a thrombophilic disorder?, Am J Hematol, 91, 39, 10.1002/ajh.24234 Álvarez-Román, 2016, Procoagulant profile in patients with immune thrombocytopenia, Br J Haematol, 175, 925, 10.1111/bjh.14412 Jy, 2013, Red cell-derived microparticles (RMP) as haemostatic agent, Thromb Haemost, 110, 751, 10.1160/TH12-12-0941 Alvarez Román, 2014, Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia, Thromb Haemost, 112, 65, 10.1160/TH13-10-0873 Vasilopoulos, 2014, Comorbidity and chronic conditions in the National Social Life, Health and Aging Project (NSHAP), Wave 2, J Gerontol B Psychol Sci Soc Sci, 69, S154, 10.1093/geronb/gbu025 Hylek, 2007, Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation, Circulation, 115, 2689, 10.1161/CIRCULATIONAHA.106.653048 Sørensen, 2009, Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data, Lancet, 374, 1967, 10.1016/S0140-6736(09)61751-7 Nørgaard, 2011, Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study, Blood, 117, 3514, 10.1182/blood-2010-10-312819 McMillan, 2008, Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura, Am J Hematol, 83, 150, 10.1002/ajh.20992 Deuson, 2012, The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim, J Med Econ, 15, 956, 10.3111/13696998.2012.688902 Snyder, 2008, Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey, Curr Med Res Opin, 24, 2767, 10.1185/03007990802377461 George, 2009, Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials, Br J Haematol, 144, 409, 10.1111/j.1365-2141.2008.07464.x Kuter, 2012, Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care, Am J Hematol, 87, 558, 10.1002/ajh.23163 Bussel, 2009, Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial, Lancet, 373, 10.1016/S0140-6736(09)60402-5 Michel, 2011, Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study, Am J Hematol, 86, 980, 10.1002/ajh.22170 Daou, 2008, Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center, Eur J Intern Med, 19, 447, 10.1016/j.ejim.2007.07.006 G., M., A., P. & L., S, 2015, Corticosteroid risk function of severe infection in primary immune thrombocytopenia adults. A nationwide nested case-control study, PLoS One, 10 M., R, 2016, Guidelines for the diagnosis, prevention and management of osteoporosis, Reumatismo, 68, 1, 10.4081/reumatismo.2016.870 Bizzoni, 2006, Idiopathic thrombocytopenic purpura (ITP) in the elderly: Clinical course in 178 patients, Eur J Haematol, 76, 210, 10.1111/j.1600-0609.2005.00602.x Cheng, 2003, Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone, N Engl J Med, 349, 831, 10.1056/NEJMoa030254 Mazzucconi, 2007, Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience, Blood, 109, 1401, 10.1182/blood-2005-12-015222 Mithoowani, 2016, High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis, Lancet Haematol, 3, e489, 10.1016/S2352-3026(16)30109-0 Wei, 2015, High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: A prospective multicenter randomized trial, Blood, 127 Hsia, 2015, Intravenous Immunoglobulin (IVIg) utilization in Immune Thrombocytopenia (ITP): a multi-center, retrospective review, Drugs, 2, 35 Caress, 2010, Safety of intravenous immunoglobulin treatment, Expert Opin Drug Saf, 9, 971, 10.1517/14740338.2010.484419 Marie, 2006, Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature, Br J Dermatol, 155, 714, 10.1111/j.1365-2133.2006.07390.x Mahévas, 2016, How we manage immune thrombocytopenia in the elderly, Br J Haematol, 173, 844, 10.1111/bjh.14067 Provan, 2015, Current Management of Primary Immune Thrombocytopenia, Adv Ther, 32, 875, 10.1007/s12325-015-0251-z Gaines, 2000, Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients, Blood, 95, 2523, 10.1182/blood.V95.8.2523 Zaja, 2010, Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia, Blood, 115, 2755, 10.1182/blood-2009-07-229815 Gudbrandsdottir, 2013, Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia, Blood, 121, 1976, 10.1182/blood-2012-09-455691 Gómez-Almaguer, 2014, Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults, Blood, 123, 3906, 10.1182/blood-2014-01-549360 Spahr, 2008, Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients, Am J Hematol, 83, 122, 10.1002/ajh.21060 Sigdel, 2012, Severe immune thrombocytopenic purpura treated with plasma exchange, Kathmandu Univ Med J, 10, 85, 10.3126/kumj.v10i1.6922 Rodeghiero, 2018, A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP, Br J Haematol, 181, 183, 10.1111/bjh.15090 Guan, 2017, Long-term results of splenectomy in adult chronic immune thrombocytopenia, Eur J Haematol, 98, 235, 10.1111/ejh.12821 Vianelli, 2013, Splenectomy as a curative treatment for immune thrombocytopenia: A retrospective analysis of 233 patients with a minimum follow up of 10 years, Haematologica, 98, 875, 10.3324/haematol.2012.075648 Gonzalez-Porras, 2013, Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia, Eur J Haematol, 91, 236, 10.1111/ejh.12146 Park, 2016, Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: A multicenter retrospective study, Acta Haematol, 135, 162, 10.1159/000442703 Delaitre, 2002, Laparoscopic splenectomy for idiopathic thrombocytopenic purpura, Surg Laparosc Endosc Percutan Tech, 12, 412, 10.1097/00129689-200212000-00005 Palandri, 2016, Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years, Am J Hematol, 91, E267, 10.1002/ajh.24310 Keidar, 2005, Analysis of outcome of laparoscopic splenectomy for idiopathic thrombocytopenic purpura by platelet count, Am J Hematol, 80, 95, 10.1002/ajh.20433 Chen, 2011, Laparoscopic splenectomy for patients with immune thrombocytopenia and very low platelet count: is platelet transfusion necessary?, J Surg Res, 170, e225, 10.1016/j.jss.2011.06.031 Boyle, 2013, Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia, Blood, 121, 4782, 10.1182/blood-2012-12-467068 Thai, 2016, Long-term complications of splenectomy in adult immune thrombocytopenia, Medicine (United States), 95 Lutwick, 2015, Overwhelming postsplenectomy infection, 629 Sarpatwari, 2010, Autologous 111In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry, Br J Haematol, 151, 477, 10.1111/j.1365-2141.2010.08377.x Khellaf, 2014, Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients, Blood, 124, 3228, 10.1182/blood-2014-06-582346 Patel, 2012, Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia, Blood, 119, 5989, 10.1182/blood-2011-11-393975 Hasan, 2009, Repeated courses of Rituximab in chronic ITP: three different regimens, Am J Hematol, 84, 661, 10.1002/ajh.21512 Chapin, 2016, Gender and duration of disease differentiate responses to rituximab–dexamethasone therapy in adults with immune thrombocytopenia, Am J Hematol, 91, 907, 10.1002/ajh.24434 Zaja, 2010, Low-dose rituximab in adult patients with primary immune thrombocytopenia, Eur J Haematol, 85, 329, 10.1111/j.1600-0609.2010.01486.x Chugh, 2015, Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis, Lancet Haematol., 2, e75, 10.1016/S2352-3026(15)00003-4 Nazi, 2013, The effect of rituximab on vaccine responses in patients with immune thrombocytopenia, Blood, 122, 1946, 10.1182/blood-2013-04-494096 Cho, 2011, Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma, Ann Hematol, 90, 111, 10.1007/s00277-010-0962-9 Gea-Banacloche, 2010, Rituximab-associated infections, Semin Hematol, 47, 187, 10.1053/j.seminhematol.2010.01.002 Dunleavy, 2010, Rituximab-associated neutropenia, Semin Hematol, 47, 180, 10.1053/j.seminhematol.2010.01.009 Carson, 2009, Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project, Blood, 113, 4834, 10.1182/blood-2008-10-186999 Wong, 2017, Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: Final results of the EXTEND study, Blood, 130, 2527, 10.1182/blood-2017-04-748707 Kuter, 2013, Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: Safety and efficacy, Br J Haematol, 161, 411, 10.1111/bjh.12260 Zhang, 2018, Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysish, Sci Rep, 8 Bussel, 2009, Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP, Blood, 113, 2161, 10.1182/blood-2008-04-150078 Cines, 2015, Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim, Int J Hematol, 102, 259, 10.1007/s12185-015-1837-6 Brynes, 2017, A 2-year, longitudinal, prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia, Acta Haematol, 137, 66, 10.1159/000452992 Janssens, 2016, Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia, Ann Hematol, 95, 10.1007/s00277-016-2682-2 Boiocchi, 2014, Bone marrow fibrosis in immune thrombocytopenia (ITP) patients treated with thrombopoietin receptor agonists (TRA)-a single center long-term follow-up, Lab. Investig., 336A, 94 Ghanima, 2011, Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents, Br J Haematol, 155, 248, 10.1111/j.1365-2141.2011.08845.x Michel, 2015, Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥65 years with immune thrombocytopenia, Ann Hematol, 94, 1973, 10.1007/s00277-015-2485-x Steurer, 2017, A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice, Eur J Haematol, 98, 112, 10.1111/ejh.12807 Gonzalez-Lopez, 2016, Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice, Eur J Haematol, 97, 297, 10.1111/ejh.12725 Bussel, 2016, Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim †, Hematology, 21, 257, 10.1179/1607845415Y.0000000041 González-López, 2015, Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia, Am J Hematol, 90, E40, 10.1002/ajh.23900 Cantoni, 2018, Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers, Am J Hematol, 93, 58, 10.1002/ajh.24935 Kuter, 2015, Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim, Int J Hematol, 101, 255, 10.1007/s12185-014-1731-7 Durand, 1991, DAPSONE for idiopathic autoimmune thrombocytopenic purpura in elderly patients, Br J Haematol, 78, 459, 10.1111/j.1365-2141.1991.tb04467.x Godeau, 1993, Dapsone for autoimmune thrombocytopenic purpura, Am J Hematol, 44, 70, 10.1002/ajh.2830440117 Zaja, 2012, Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab, Am J Hematol, 87, 321, 10.1002/ajh.22266 Godeau, 1997, Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases, Br J Haematol, 97, 336, 10.1046/j.1365-2141.1997.412687.x Sauvetre, 2015, Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases, Am J Hematol, 90, E201, 10.1002/ajh.24068 Liu, 2016, The effect of Danazol in primary immune thrombocytopenia: An analysis of a large cohort from a single center in China, Clin Appl Thromb, 22, 727, 10.1177/1076029615622002 Ahn, 1983, Danazol for the treatment of idiopathic thrombocytopenic purpura, N Engl J Med, 308, 1396, 10.1056/NEJM198306093082306 Maloisel, 2004, Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: Long-term results, Am J Med, 116, 590, 10.1016/j.amjmed.2003.12.024 Ahn, 1987, Low-dose danazol therapy in idiopathic thrombocytopenic purpura, Ann Intern Med, 107, 177, 10.7326/0003-4819-107-2-177 Audia, 2016, Is there still a place for ‘old therapies’ in the management of immune thrombocytopenia?, Rev Med Interne, 37, 43, 10.1016/j.revmed.2015.08.007 Sussman, 1967, Azathioprine in refractory idiopathic thrombocytopenic purpura, JAMA, 202, 259, 10.1001/jama.1967.03130170059006 Taylor, 2015, Mycophenolate mofetil therapy for severe immune thrombocytopenia, Br J Haematol, 171, 625, 10.1111/bjh.13622 Kappers-Klunne, 2001, Cyclosporin a for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy, Br J Haematol, 114, 121, 10.1046/j.1365-2141.2001.02893.x Khellaf, 2014, Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies, Am J Hematol, 89, 194, 10.1002/ajh.23609 Stirnemann, 2016, Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients, Eur J Haematol, 96, 269, 10.1111/ejh.12586 Sikorska, 2004, The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia, Clin Lab Haematol, 26, 407, 10.1111/j.1365-2257.2004.00643.x